ヒト遺伝学市場

The secondary research process involved comprehensive analysis of genomic databases, regulatory filings, peer-reviewed genetic research journals, and authoritative public health repositories. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH), European Medicines Agency (EMA), National Institutes of Health (NIH) National Human Genome Research Institute (NHGRI), National Center for Biotechnology Information (NCBI) GenBank & ClinVar databases, Centers for Medicare & Medicaid Services (CMS), Centers for Disease Control and Prevention (CDC) Office of Genomics and Precision Public Health, World Health Organization (WHO) Human Genomics Programme, European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI), Online Mendelian Inheritance in Man (OMIM), American College of Medical Genetics and Genomics (ACMG), European Society of Human Genetics (ESHG), International Society for Pharmacogenomics (ISP), UK National Health Service (NHS) Genomic Medicine Service, EU European Health Data and Evidence Network (EHDEN), Organisation for Economic Co-operation and Development (OECD) Health Statistics, and national genomic medicine strategies from key markets. These sources were utilized to collect genetic testing volume statistics, regulatory approval data for NGS-based assays, clinical utility studies, genomic biomarker validation data, reimbursement frameworks, and population-scale genomic screening program metrics across hereditary cancer testing, prenatal screening (NIPT), pharmacogenomic testing, and rare disease diagnostic categories.

Supply-side and demand-side stakeholders were interviewed during the primary research process to acquire qualitative and quantitative insights from various perspectives within the human genetics value chain. Chief Executive Officers, Chief Scientific Officers, Vice Presidents of Genomic Research and Development, Heads of Regulatory Affairs for In Vitro Diagnostics (IVD), and commercial directors from molecular diagnostics OEMs, genetic testing laboratories, bioinformatics solution providers, and NGS platform manufacturers comprised the supply-side sources. Board-certified medical geneticists, molecular pathologists, laboratory directors from hospital-based and reference laboratories, genetic counselors, precision medicine program directors from academic medical centers, and procurement leads from integrated health networks and research institutions comprised demand-side sources. Primary research has validated market segmentation across test modalities, confirmed CLIA-certification and CAP-accreditation timelines for new laboratory-developed tests (LDTs), gathered insights on clinical adoption patterns for whole-genome versus targeted gene panels, pricing dynamics for direct-to-consumer genetic testing versus clinical-grade testing, and developed reimbursement navigation strategies for preventive genomic screening.

Primary Respondent Breakdown:

By Designation: C-level Primaries (32%), Director Level (35%), Others (33%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Global market valuation was derived through revenue mapping and genetic testing procedure volume analysis across diagnostic, preventive, and wellness application segments. The methodology included:

The identification of over 50 significant manufacturers and service providers in North America, Europe, Asia-Pacific, and Latin America, including molecular diagnostic companies (Myriad Genetics, Labcorp), NGS platform vendors (Illumina, Thermo Fisher Scientific), and bioinformatics providers

Product mapping across NIPT, carrier screening, pharmacogenomic testing, karyotype analysis, thrombophilia testing, Septin 9 biomarker testing, and comprehensive NGS-based applications

Analysis of reported and modeled annual revenues specific to human genetics portfolios, including instrument sales, consumables, and testing services revenue

Coverage of manufacturers and service providers representing 70-75% of global market share in 2024

Extrapolation using bottom-up (test volume × average selling price by country/region, segmented by test type and clinical indication) and top-down (manufacturer revenue validation and bioinformatics services quantification) approaches to derive segment-specific valuations for diagnostic & treatment, preventive medicine, and wellness & e-commerce applications

Cross-validation against national genomic medicine spending data, insurance claims databases for genetic testing procedures, and direct-to-consumer genetic testing market tracking